Target intelligence / Profile preview

Sortase A (SrtA)

Target
SrtA
Molecular classification
Enzyme, Cysteine transpeptidase, Peptidase (MEROPS family C60), Membrane-associated protein
01

Overview

Sortase A is a membrane-associated cysteine transpeptidase found predominantly in Gram-positive bacteria such as *Staphylococcus aureus*. It catalyzes the covalent anchoring of specific surface proteins containing an LPXTG motif to the peptidoglycan layer of the bacterial cell wall. The enzyme recognizes this sorting signal at protein C termini, cleaves between threonine and glycine residues within this motif using its active-site cysteine thiol group, forms an acyl-enzyme intermediate with threonine’s carboxyl group, then resolves this intermediate via nucleophilic attack from amino groups on lipid II precursors—ultimately linking proteins to peptidoglycan. This process is essential for displaying many virulence factors required for host colonization and infection. Because it plays a central role in pathogenesis but is not required for bacterial viability under all conditions, Sortase A has emerged as an attractive target for antivirulence therapies designed to disarm rather than kill pathogenic bacteria.

Other names
SrtAStaphylococcus aureus sortase AHousekeeping sortase
02

Mechanism of action

Drugs or inhibitors targeting Sortase A typically act by blocking its active site cysteine residue or interfering with substrate binding, thereby preventing covalent attachment of virulence factors to the cell wall. This disrupts bacterial colonization without necessarily killing bacteria directly ("anti-infective" or "antivirulence" mechanism).

03

Biological functions

Covalent attachment of surface proteins to the peptidoglycan cell wall in Gram-positive bacteriaAnchoring of virulence factors to the bacterial surfaceProtein ligation (transpeptidation)
04

Disease associations

Infection (notably in Staphylococcus aureus and other Gram-positive pathogens)Essential for host colonization and pathogenesis in invasive diseases
05

Safety considerations

Potential off-target effects (no human homologs known)Possible development of resistance mechanisms by bacteriaChallenges translating enzyme inhibition into clinical efficacy since it does not kill bacteria but reduces their pathogenicity ("anti-infective" rather than bactericidal approach)
06

Interacting drugs

Small-molecule inhibitors (general, e.g., trans-chalcone, synthetic inhibitors, peptide-based compounds)

1 more in the full profile.

07

Biomarkers

No specific biomarkers for patient selection or efficacy monitoring mentioned

Beyond the preview

Go deeper on Sortase A (SrtA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sortase A (SrtA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call